Grant: Engage Grants Program
University of Guelph
$25,000.00
Manufacturing hydrolized phytoglycogen nanoparticles at multi-kilogram scale
EF 2019-20
Résumé
Mirexus Biotechnologies Inc., based in Guelph, ON, has developed a water-based process to extract naturally occurring phytoglycogen nanoparticles (PhG) from sweet corn. These nanoparticles are uniform in size (i.e. monodisperse), non-toxic and non-immunogenic. They are also highly amenable to chemical modification. These characteristics position PhG as an attractive biocompatible nano-platform technology. Mirexus recently developed several methods of generating size-reduced material through acid/heat hydrolysis or via enzymatic digestion of PhG. Biological testing of the hydrolysed material has uncovered unique properties including enhanced reduction of reactive oxygen species, upregulation of repair proteins, and decreased melanogenesis in skin cells. Manufacturing hydrolyzed multi-kilogram-scale material would enable Mirexus to launch hydrolyzed PhG as a novel ingredient for personal care applications (native PhG is already well-positioned in this market). While acid/heat treatment is effective at generating hydrolyzed material, the production facility's current infrastructure does not have the pH required to produce this material. Mirexus' current production set-up is compatible with enzymatic digestion; however, the time required to produce uniformly-hydrolyzed material greatly increases the cost of goods. The goal of this research project is to develop an economical and scalable manufacturing process for a new class of nanoparticle-phytoglycogen-which is core to the success of Mirexus' business/operations, representing a significant source of revenue for the company. Expansion of PhG-based technologies within the market demands methodologies that enable scalable production of modified material, which can be easily integrated into Mirexus' production process. Mirexus currently lacks the infrastructure and expertise required to develop these methodologies; thus, it is imperative that they collaborate with academic partners such as Dr. Martinez. Mirexus is a Canadian company based in Guelph ON. Expanding PhG-based product lines will lead to increased global demand for this patented technology (>95% of revenue will be from exports), growth of the company, and ultimately, creation of more high-tech jobs for Canadians. This will directly benefit the Canadian economy. Because we intend to bring the results of this work to market within a year, it is anticipated that these high-tech jobs will be created within the next two years.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
537996-2019
Name nom
Martinez, Mario
Department département
Engineering, School of
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2019
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3754
Research subject group en
Polymer chemistry
Research subject group fr
Chimie des polymères
Research subject en
Biopolymers
Research subject fr
Biopolymères
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Manufacturing hydrolized phytoglycogen nanoparticles at multi-kilogram scale
Keyword
NSERC
Application summary
Mirexus Biotechnologies Inc., based in Guelph, ON, has developed a water-based process to extract naturally occurring phytoglycogen nanoparticles (PhG) from sweet corn. These nanoparticles are uniform in size (i.e. monodisperse), non-toxic and non-immunogenic. They are also highly amenable to chemical modification. These characteristics position PhG as an attractive biocompatible nano-platform technology. Mirexus recently developed several methods of generating size-reduced material through acid/heat hydrolysis or via enzymatic digestion of PhG. Biological testing of the hydrolysed material has uncovered unique properties including enhanced reduction of reactive oxygen species, upregulation of repair proteins, and decreased melanogenesis in skin cells. Manufacturing hydrolyzed multi-kilogram-scale material would enable Mirexus to launch hydrolyzed PhG as a novel ingredient for personal care applications (native PhG is already well-positioned in this market). While acid/heat treatment is effective at generating hydrolyzed material, the production facility's current infrastructure does not have the pH required to produce this material. Mirexus' current production set-up is compatible with enzymatic digestion; however, the time required to produce uniformly-hydrolyzed material greatly increases the cost of goods. The goal of this research project is to develop an economical and scalable manufacturing process for a new class of nanoparticle-phytoglycogen-which is core to the success of Mirexus' business/operations, representing a significant source of revenue for the company. Expansion of PhG-based technologies within the market demands methodologies that enable scalable production of modified material, which can be easily integrated into Mirexus' production process. Mirexus currently lacks the infrastructure and expertise required to develop these methodologies; thus, it is imperative that they collaborate with academic partners such as Dr. Martinez. Mirexus is a Canadian company based in Guelph ON. Expanding PhG-based product lines will lead to increased global demand for this patented technology (>95% of revenue will be from exports), growth of the company, and ultimately, creation of more high-tech jobs for Canadians. This will directly benefit the Canadian economy. Because we intend to bring the results of this work to market within a year, it is anticipated that these high-tech jobs will be created within the next two years.